Company Profile

HeartWare Inc (AKA: HeartWare International Inc)
Profile last edited on: 6/4/2024      CAGE: 5DW37      UEI: D4D5TGHLXE71

Business Identifier: Implantable Left Ventricular Assist Devices ("LVADs") for treatment of advanced heart failure.
Year Founded
2003
First Award
2011
Latest Award
2014
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

500 Old Connecticut Path
Framingham, MA 01701
   (508) 739-0950
   cs@heartwareinc.com
   www.heartwareinc.com
Location: Multiple
Congr. District: 05
County: Middlesex

Public Profile

Hedquartered in Framingham, MA, with Operations, Manufacturing and Distribution in FL, MN, Germany and Australia, HeartWare International, Inc. develops and manufactures small implantable heart pumps or ventricular assist devices for the treatment of advanced heart failure. Having recently outgrown SBIR size limitations through an active program of acquisitions, the company offers HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories, and surgical tools designed to provide circulatory support for patients in the advanced stage of heart failure. HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 37 countries. The device is also currently the subject of a U.S. clinical trial for destination therapy.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : HTWR
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 2 NIH $4,006,031
Project Title: Feasibility Testing of Miniaturized Ventricular Assist Device (Mvad)

Key People / Management

  Douglas E Godshall -- CEO

  Dave Hathaway -- Chief Medical Officer

  Ray Larkin Jr -- Chairman and Director

  Jeff LaRose -- Executive VP and CSO

  Jim Schuermann -- Senior VP of Sales and Marketing

  Daniel Tamez